{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:20:18Z","timestamp":1785604818849,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The University of Osaka"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Systemic chemotherapy is the standard treatment for esophageal cancer with synchronous distant metastasis including para-aortic lymph node (PALN) metastasis. The significance of conversion surgery for esophageal cancer with synchronous PALN metastasis remains controversial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The current study aimed to investigate the clinical outcome of conversion surgery for esophageal cancer with synchronous PALN metastasis after induction therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This multi-institutional retrospective study included 48 patients with esophageal cancer who exhibited synchronous PALN metastasis and who received induction chemotherapy or chemoradiotherapy followed by conversion surgery between 2005 and 2022. The short- and long-term treatment outcomes were examined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 48 patients, 45 and 3 received chemotherapy and chemoradiotherapy, respectively, as the initial treatment. Moreover, all patients underwent subtotal esophagectomy. The incidence rate of postoperative complications was 48% and the in-hospital mortality rate was 2%. The 3- and 5-year overall survival rates of all patients were 36.1% and 25.2%, respectively. The overall survival rates of patients with pN2-3 and final PALN status (fM1) were significantly lower than that of patients with pN0-1 (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.0025) and fM0 (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.0043). The multivariate analysis showed that pathological nodal status (hazard ratio 2.44, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.0488) and fM status (hazard ratio 2.53, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.0246) were independent prognostic factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Conversion surgery for esophageal cancer with synchronous PALN metastasis is feasible and promising. In addition, conversion surgery for patients with controlled nodal status including PALN metastasis is important for long-term prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-18042-w","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:29:00Z","timestamp":1755696540000},"page":"9270-9280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcome of Conversion Surgery After Induction Therapy for Esophageal Cancer with Synchronous Para-Aortic Lymph Node Metastasis: A Multi-institutional Retrospective Study"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-9388","authenticated-orcid":false,"given":"Koji","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Momose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Sugase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Motoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Fujitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takushi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"2","key":"18042_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1442-2050.2011.01222.x","volume":"25","author":"K Tanaka","year":"2012","unstructured":"Tanaka K, Yano M, Motoori M, et al. The significance of abdominal para-aortic lymph node metastasis in patients with lower thoracic esophageal cancer. Dis Esophagus. 2012;25(2):146\u201352.","journal-title":"Dis Esophagus."},{"issue":"4","key":"18042_CR2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.21873\/invivo.13269","volume":"37","author":"A Kawata","year":"2023","unstructured":"Kawata A, Miyamoto Y, Fukubayashi K, et al. Conversion surgery after encorafenib plus cetuximab for chemorefractory BRAF V600E-mutated colorectal cancer with para-aortic lymph node metastases. In Vivo. 2023;37(4):1797\u2013801.","journal-title":"In Vivo"},{"issue":"1","key":"18042_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40792-018-0494-4","volume":"4","author":"A Serizawa","year":"2018","unstructured":"Serizawa A, Taniguchi K, Yamada T, et al. Successful conversion surgery for unresectable gastric cancer with giant para-aortic lymph node metastasis after downsizing chemotherapy with S-1 and oxaliplatin: a case report. Surg Case Rep. 2018;4(1):88.","journal-title":"Surg Case Rep."},{"issue":"1","key":"18042_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s13691-021-00516-9","volume":"11","author":"Y Ushimaru","year":"2022","unstructured":"Ushimaru Y, Nishikawa K, Yasuhara Y, et al. Successful laparoscopic conversion surgery for gastric cancer with para-aortic lymph node metastasis after third-line chemotherapy: a case report. Int Cancer Conf J. 2022;11(1):50\u20136.","journal-title":"Int Cancer Conf J."},{"issue":"12","key":"18042_CR5","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s00595-024-02872-4","volume":"54","author":"T Shigeno","year":"2024","unstructured":"Shigeno T, Kajiyama D, Sato K, et al. Efficiency of conversion surgery for esophageal squamous cell carcinoma with solitary abdominal para-aortic lymph node metastasis. Surg Today. 2024;54(12):1490\u20137.","journal-title":"Surg Today."},{"issue":"3","key":"18042_CR6","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1245\/s10434-023-14562-5","volume":"31","author":"S Igaue","year":"2024","unstructured":"Igaue S, Nozaki R, Utsunomiya D, et al. Significance of surgery for resectable M1 lymph node metastases without organ metastasis in esophageal carcinoma in the era of neoadjuvant treatment. Ann Surg Oncol. 2024;31(3):1525\u201335.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"18042_CR7","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/cancers16071376","volume":"16","author":"D Marrelli","year":"2024","unstructured":"Marrelli D, Piccioni SA, Carbone L, et al. Posterior and para-aortic (D2plus) lymphadenectomy after neoadjuvant\/conversion therapy for locally advanced\/oligometastatic gastric cancer. Cancers. 2024;16(7):1376.","journal-title":"Cancers."},{"issue":"2","key":"18042_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M, et al. International retrospective cohort study of conversion therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2022;6(2):227\u201340.","journal-title":"Ann Gastroenterol Surg."},{"issue":"1","key":"18042_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdw439","volume":"28","author":"M Yamasaki","year":"2017","unstructured":"Yamasaki M, Yasuda T, Yano M, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28(1):116\u201320.","journal-title":"Ann Oncol."},{"issue":"5\u20136","key":"18042_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000329806","volume":"80","author":"M Yamasaki","year":"2011","unstructured":"Yamasaki M, Miyata H, Tanaka K, et al. Multicenter phase I\/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80(5\u20136):307\u201313.","journal-title":"Oncology."},{"issue":"10447","key":"18042_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024;404(10447):55\u201366.","journal-title":"Lancet."},{"issue":"1","key":"18042_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdw439","volume":"28","author":"M Yamasaki","year":"2017","unstructured":"Yamasaki M, Yasuda T, Yano M, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28(1):116\u201320.","journal-title":"Ann Oncol."},{"issue":"4","key":"18042_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11748-016-0626-3","volume":"64","author":"K Yamashita","year":"2016","unstructured":"Yamashita K, Katada N, Moriya H, et al. Neoadjuvant chemotherapy of triplet regimens of docetaxel\/cisplatin\/5-FU (DCF NAC) may improve patient prognosis of cStage II\/III esophageal squamous cell carcinoma-propensity score analysis. Gen Thorac Cardiovasc Surg. 2016;64(4):209\u201315.","journal-title":"Gen Thorac Cardiovasc Surg."},{"issue":"5","key":"18042_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362.","journal-title":"N Engl J Med."},{"key":"18042_CR15","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Amsterdam: Wiley; 2017."},{"issue":"4","key":"18042_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/cas.12622","volume":"106","author":"M Shinoda","year":"2015","unstructured":"Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407\u201312.","journal-title":"Cancer Sci."},{"issue":"9","key":"18042_CR17","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1200\/JCO.1999.17.9.2915","volume":"17","author":"A Ohtsu","year":"1999","unstructured":"Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and\/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17(9):2915\u201321.","journal-title":"J Clin Oncol."},{"issue":"4","key":"18042_CR18","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ijrobp.2014.03.030","volume":"89","author":"K Higuchi","year":"2014","unstructured":"Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501\u2013P2). Int J Radiat Oncol Biol Phys. 2014;89(4):872\u20139.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"18042_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","volume":"21","author":"S Mine","year":"2024","unstructured":"Mine S, Tanaka K, Kawachi H, et al. Japanese classification of esophageal cancer, 12th Edition: Part I. Esophagus. 2024;21(3):179\u2013215.","journal-title":"Esophagus."},{"issue":"3","key":"18042_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s10388-024-01048-w","volume":"21","author":"Y Doki","year":"2024","unstructured":"Doki Y, Tanaka K, Kawachi H, et al. Japanese classification of esophageal cancer, 12th Edition: Part II. Esophagus. 2024;21(3):216\u201369.","journal-title":"Esophagus."},{"issue":"7","key":"18042_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s11748-016-0650-3","volume":"64","author":"MA Cuesta","year":"2016","unstructured":"Cuesta MA, van der Wielen N, Straatman J, van der Peet DL. Video-assisted thoracoscopic esophagectomy: keynote lecture. Gen Thorac Cardiovasc Surg. 2016;64(7):380\u20135.","journal-title":"Gen Thorac Cardiovasc Surg."},{"issue":"8","key":"18042_CR22","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1245\/s10434-021-09962-4","volume":"28","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Yamasaki M, Sugimura K, et al. Thoracic duct resection has a favorable impact on prognosis by preventing hematogenous spread of esophageal cancer cells: a multi-institutional analysis of 2269 patients. Ann Surg Oncol. 2021;28(8):4402\u201310.","journal-title":"Ann Surg Oncol."},{"issue":"Suppl 8","key":"18042_CR23","doi-asserted-by":"publisher","first-page":"S834","DOI":"10.21037\/jtd.2017.03.151","volume":"9","author":"S van der Horst","year":"2017","unstructured":"van der Horst S, Weijs TJ, Ruurda JP, et al. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum. J Thorac Dis. 2017;9(Suppl 8):S834\u201342.","journal-title":"J Thorac Dis."},{"issue":"Suppl 3","key":"18042_CR24","doi-asserted-by":"publisher","first-page":"S1350","DOI":"10.1245\/s10434-015-4544-x","volume":"22","author":"PC van der Sluis","year":"2015","unstructured":"van der Sluis PC, Ruurda JP, Verhage RJ, et al. Oncologic long-term results of robot-assisted minimally invasive thoraco-laparoscopic esophagectomy with two-field lymphadenectomy for esophageal cancer. Ann Surg Oncol. 2015;22(Suppl 3):S1350-1356.","journal-title":"Ann Surg Oncol."},{"issue":"Suppl","key":"18042_CR25","first-page":"2","volume":"33","author":"EM de Groot","year":"2020","unstructured":"de Groot EM, van der Horst S, Kingma BF, et al. Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open esophagectomy: long-term follow-up of a randomized clinical trial. Dis Esophagus. 2020;33(Suppl):2.","journal-title":"Dis Esophagus."},{"issue":"2","key":"18042_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jso.20194","volume":"89","author":"H Wada","year":"2005","unstructured":"Wada H, Doki Y, Nishioka K, et al. Clinical outcome of esophageal cancer patients with history of gastrectomy. J Surg Oncol. 2005;89(2):67\u201374.","journal-title":"J Surg Oncol."},{"issue":"8","key":"18042_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11748-016-0661-0","volume":"64","author":"M Watanabe","year":"2016","unstructured":"Watanabe M, Mine S, Nishida K, Kurogochi T, Okamura A, Imamura Y. Reconstruction after esophagectomy for esophageal cancer patients with a history of gastrectomy. Gen Thorac Cardiovasc Surg. 2016;64(8):457\u201363.","journal-title":"Gen Thorac Cardiovasc Surg."},{"issue":"1","key":"18042_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s10388-022-00958-x","volume":"20","author":"K Tanaka","year":"2023","unstructured":"Tanaka K, Yamasaki M, Yamashita K, et al. Safety and efficacy of double-tract reconstruction with remnant stomach conservation in esophagectomy for patients with a history of distal gastrectomy. Esophagus. 2023;20(1):72\u201380.","journal-title":"Esophagus."},{"issue":"2","key":"18042_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg."},{"issue":"1","key":"18042_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1245\/s10434-024-16196-7","volume":"32","author":"T Tsuji","year":"2025","unstructured":"Tsuji T, Matsuda S, Sato Y, et al. Safety and efficacy of conversion therapy after systemic chemotherapy in advanced esophageal cancer with distant metastases: a multicenter retrospective observational study. Ann Surg Oncol. 2025;32(1):274\u201383.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"18042_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","volume":"158","author":"TD Azad","year":"2020","unstructured":"Azad TD, Chaudhuri AA, Fang P, et al. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology. 2020;158(3):494\u2013505.","journal-title":"Gastroenterology."},{"issue":"12","key":"18042_CR32","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842\u201353.","journal-title":"Cancer Discov."},{"issue":"1","key":"18042_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2020.09.035","volume":"160","author":"T Iwaya","year":"2021","unstructured":"Iwaya T, Endo F, Takahashi F, Tokino T, Sasaki Y, Nishizuka SS. Frequent tumor burden monitoring of esophageal squamous cell carcinoma with circulating tumor DNA using individually designed digital polymerase chain reaction. Gastroenterology. 2021;160(1):463-465.e4.","journal-title":"Gastroenterology."},{"issue":"6","key":"18042_CR34","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1245\/s10434-023-13194-z","volume":"30","author":"Y Morimoto","year":"2023","unstructured":"Morimoto Y, Matsuda S, Kawakubo H, et al. Tumor burden monitoring with circulating tumor DNA during treatment in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2023;30(6):3747\u201356.","journal-title":"Ann Surg Oncol."},{"issue":"10302","key":"18042_CR35","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18042-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:40:44Z","timestamp":1760715644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18042-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["18042"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18042-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Koji Tanaka, Keijiro Sugimura, Norihiro Matsuura, Osamu Shiraishi, Kota Momose, Kotaro Yamashita, Takahito Sugase, Takashi Kanemura, Tomoki Makino, Atsushi Takeno, Ryohei Kawabata, Masaaki Motoori, Yutaka Kimura, Makoto Yamasaki, Hiroshi Miyata, Kazumasa Fujitani, Takushi Yasuda, Masahiko Yano, Hidetoshi Eguchi, Yuichiro and Doki have no disclosures to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}